Cargando…

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma

PURPOSE: Patients with relapsed or refractory primary mediastinal large B-cell lymphoma (rrPMBCL) have a poor prognosis, and their treatment represents an urgent and unmet need. Because PMBCL is associated with genetic aberrations at 9p24 and overexpression of programmed cell death-1 (PD-1) ligands...

Descripción completa

Detalles Bibliográficos
Autores principales:	Armand, Philippe, Rodig, Scott, Melnichenko, Vladimir, Thieblemont, Catherine, Bouabdallah, Kamal, Tumyan, Gayane, Özcan, Muhit, Portino, Sergio, Fogliatto, Laura, Caballero, Maria D., Walewski, Jan, Gulbas, Zafer, Ribrag, Vincent, Christian, Beth, Perini, Guilherme Fleury, Salles, Gilles, Svoboda, Jakub, Zain, Jasmine, Patel, Sanjay, Chen, Pei-Hsuan, Ligon, Azra H., Ouyang, Jing, Neuberg, Donna, Redd, Robert, Chatterjee, Arkendu, Balakumaran, Arun, Orlowski, Robert, Shipp, Margaret, Zinzani, Pier Luigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2019
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881098/ https://www.ncbi.nlm.nih.gov/pubmed/31609651 http://dx.doi.org/10.1200/JCO.19.01389

Ejemplares similares

Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170
por: Zinzani, Pier Luigi, et al.
Publicado: (2023)

Pembrolizumab in relapsed or refractory Richter syndrome
por: Armand, Philippe, et al.
Publicado: (2020)

Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087
por: Chen, Robert, et al.
Publicado: (2015)

An open-label, multicohort Phase Ib trial of pembrolizumab (MK-3475) for advanced hematologic malignancies: KEYNOTE-013
por: Ribrag, Vincent, et al.
Publicado: (2015)

P1351: CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION SAFETY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER PEMBROLIZUMAB THERAPY
por: Kuruvilla, J., et al.
Publicado: (2022)

A Case of Primary Hyperaldosteronism Presenting as Hemorrhagic Stroke
por: Anjum, Azeen, et al.
Publicado: (2021)

SAT-LB54 Acute Sterile Meningitis as a Primary Manifestation of Pituitary Apoplexy
por: Tumyan, Gayane, et al.
Publicado: (2020)

Acute Sterile Meningitis as a Primary Manifestation of Pituitary Apoplexy
por: Tumyan, Gayane, et al.
Publicado: (2020)

Sebaceous Carcinoma Masquerading As Orbital Cellulitis
por: Ramachandran, Vignesh, et al.
Publicado: (2022)

Supportive Care in Hemato-Oncology: A Review in Light of the Latest Guidelines
por: Gündüz, Eren, et al.
Publicado: (2012)

PB2358: PHASE 1-2 STUDY OF THE SAFETY, PK, PD, AND PRELIMINARY ACTIVITY OF TOLINAPANT IN COMBINATION WITH ORAL DECITABINE/CEDAZURIDINE AND ORAL DECITABINE/CEDAZURIDINE ALONE IN SUBJECTS WITH R/R PTCL
por: Shortt, Jake, et al.
Publicado: (2023)

Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study
por: Younes, Anas, et al.
Publicado: (2016)

Work-up and management of a high-risk patient with primary central nervous system lymphoma
por: Zeynalova, Pervin A., et al.
Publicado: (2016)

Primary Pleural Diffuse Large B-cell non-Hodgkin’s Lymphoma Diagnosed via [18F]-2-Fluoro-Deoxy-DGlucose Positron Emission Tomography /Computed Tomography
por: Sivrikoz, İlknur Ak, et al.
Publicado: (2012)

Immunohistochemical Detection of MYC-driven Diffuse Large B-Cell Lymphomas
por: Kluk, Michael J., et al.
Publicado: (2012)

PB1948: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
por: Byalik, Tatyana, et al.
Publicado: (2023)

CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas
por: Chen, Linfeng, et al.
Publicado: (2020)

Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It?
por: Akay, Olga Meltem, et al.
Publicado: (2016)

PSUN24 Adrenal Metastases Treated with Radiotherapy: Development of Adrenal Insufficiency
por: Tumyan, Gayane, et al.
Publicado: (2022)

The Frequency and Clinical Relevance of Multidrug Resistance Protein Expression in Patients with Lymphoma
por: Gündüz, Eren, et al.
Publicado: (2012)

Unusual Manifestations of Vincristine Neuropathy: Report of Two Cases of Hodgkin Lymphoma
por: Akay, Olga Meltem, et al.
Publicado: (2014)

Non-Leukemic Granulocytic Sarcoma Presenting with Multiple Lymphadenopathies
por: Gedük, Ayfer, et al.
Publicado: (2017)

Are the High Serum Interleukin-6 and Vascular Endothelial Growth Factor Levels Useful Prognostic Markers in Aggressive Non-Hodgkin Lymphoma Patients?
por: Üsküdar Teke, Hava, et al.
Publicado: (2015)

Survival outcomes with warfarin compared with direct oral anticoagulants in cancer-associated venous thromboembolism in the United States: A population-based cohort study
por: Khan, Adeel M., et al.
Publicado: (2022)

Efficacy, Safety and Steroid-sparing Effect of Topical Cyclosporine A 0.05% for Vernal Keratoconjunctivitis in Indian Children
por: Chatterjee, Arkendu, et al.
Publicado: (2019)

Pembrolizumab (MK-3475) in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-023
por: Mateos, Maria-Victoria, et al.
Publicado: (2015)

Blastic Plasmacytoid Dendritic Cell Leukemia Successfully Treated by Autologous Hematopoietic Stem Cell Transplantation to a Remission of 48-Month Duration
por: Goren Sahin, Deniz, et al.
Publicado: (2013)

High-dose chemotherapy followed by autologous stem cell transplantation for adult patients With first relapse of Ewing’s sarcoma: A single institution experience
por: Paksoy, Nail, et al.
Publicado: (2022)

Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective
por: Sureda, Anna, et al.
Publicado: (2020)

P1079: VERY LONG-TERM FOLLOW-UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY.
por: Sarkozy, Clementine, et al.
Publicado: (2023)

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study
por: Zinzani, Pier Luigi, et al.
Publicado: (2023)

Diffuse large B-cell lymphomas have spatially defined, tumor immune microenvironments revealed by high-parameter imaging
por: Wright, Kyle T., et al.
Publicado: (2023)

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
por: Armand, Philippe, et al.
Publicado: (2023)

PB2259: THE NEW PD-1 INHIBITOR PROLGOLIMAB IN THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN’S LYMPHOMA
por: Semenova, Anastasia, et al.
Publicado: (2023)

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
por: Dreyling, M., et al.
Publicado: (2017)

PB2309: OUTCOMES OF 22 PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: SINGLE INSTITUTE EXPERIENCE
por: Tumyan, Gayane, et al.
Publicado: (2023)

Frontal osteomyelitis presenting as upper eyelid ectropion: A cautionary tale
por: Bandyopadhyay, Rakhi, et al.
Publicado: (2015)

Exfoliated black phosphorous-mediated CuAAC chemistry for organic and macromolecular synthesis under white LED and near-IR irradiation
por: Kocaarslan, Azra, et al.
Publicado: (2021)

Base-Resistant Ionic Metal-Organic Framework as a Porous Ion-Exchange Sorbent
por: Desai, Aamod V., et al.
Publicado: (2018)

Clinical Importance of CDKN2A Loss and Monosomy 10 in Pilocytic Astrocytoma
por: Cagney, Daniel N, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9dom7top4b2ldc7ub686odc7f2